Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$1.43B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.21B
EBITDA Margin
-2.25%
TTM Avg
-29.69%
3Y Avg
-65.15%
5Y Avg
-190.58%
Market Cap
$1.20B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.46B
EBITDA Margin
21.45%
TTM Avg
-50.92%
3Y Avg
-538.26%
5Y Avg
-378.46%
Market Cap
$1.16B
EBITDA Margin
21.67%
TTM Avg
19.38%
3Y Avg
14.20%
5Y Avg
2.75%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | $1.33B | N/A | N/A | N/A | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.34B | N/A | N/A | N/A | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.24B | N/A | N/A | N/A | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Cronos Group Inc. (CRON)vs › | $1.21B | -2.25% | -29.69% | -65.15% | -190.58% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.46B | 21.45% | -50.92% | -538.26% | -378.46% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 21.67% | 19.38% | 14.20% | 2.75% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.51B | N/A | N/A | N/A | N/A |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.14B | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
